Avacta Progresses Tumour-Targeted Oncology Programmes and Extends Cash Runway Into Q3 2026

Avacta Group plc (LSE:AVCT) reported solid operational and research progress during 2025, underpinned by encouraging clinical data and continued advancement of its proprietary tumour-activated drug delivery platform. Updated results from Phase 1b expansion cohorts of faridoxorubicin (AVA6000) showed supportive efficacy and safety signals in salivary gland cancer, while patient enrolment continued to help refine trial design ahead of later-stage studies.

The company also moved its second pre|CISION® programme, FAP-Exd (AVA6103), further forward, supported by positive pharmacology data. A Phase 1 trial is scheduled to begin in early 2026 across multiple specialist oncology centres in the US, targeting four AI-selected tumour types. Alongside programme execution, Avacta introduced additional platform innovations, including a sustained-release mechanism and a dual-payload delivery technology, aimed at broadening the potential applications of its platform.

On the financial side, Avacta raised £22.5 million in equity during 2025 and finished the year with £16.9 million in cash and equivalents. This funding is expected to support operations into the third quarter of 2026, allowing the company to reach key data readouts for both AVA6000 and AVA6103. Management also confirmed that partnering discussions remain active, which could influence the structure, funding and risk profile of future pivotal trials and wider pipeline development.

More about Avacta Group plc

Avacta Group plc is a clinical-stage biopharmaceutical company focused on oncology, developing its proprietary pre|CISION® tumour-activated drug delivery platform. Its lead programmes, faridoxorubicin (AVA6000) and FAP-Exd (AVA6103), are designed to release chemotherapy agents directly within tumours at high concentrations while limiting systemic toxicity. The company targets difficult-to-treat solid cancers including salivary gland, pancreatic, gastric, small cell lung and cervical cancers, with a strategy centred on platform expansion, intellectual property development and collaboration with global pharmaceutical partners.